Skip to main content

Month: August 2021

Mirasol Resources Reports on Drill Program at Sascha Marcelina Project in Argentina

Encouraging Au/Ag and Base Metal Mineralization Identified VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) — Mirasol Resources Ltd. (TSX-V: MRZ) (OTCPK: MRZLF) (the “Company” or “Mirasol”) is pleased to report the results from the recently completed 2,814m drill program at the Sascha Marcelina Project (“Sascha Marcelina”) in Santa Cruz province, Argentina. Mirasol’s President, Tim Heenan, commented: “We are encouraged with the early results from this maiden drill program on three of our priority prospects within the Sascha Marcelina project. The Pellegrini Trend returned a broad zone of Au and Ag mineralization overprinting a younger Pb and Zn rich base metal pulse, that is interpreted to represent the high-level expression in this epithermal system. This mineralized zone may correspond to the top or the margins of...

Continue reading

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel Continues Expansion of AVB-500 in Multiple Oncology Indications and Combinations HOUSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) — Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the Company has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma. The Phase 1b portion of the clinical trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with gemcitabine and nab-paclitaxel. “We are pleased with...

Continue reading

QuoteMedia Q2 2021 Financial Results and Investors’ Conference Call August 12, 2021

PHOENIX, Aug. 09, 2021 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, today announced that its earnings for its quarter ended June 30, 2021 will be released the morning of August 12, 2021. That same day, the company will host a conference call at 2:00 PM Eastern time to discuss the financial results and provide a business update. Conference Call Details: Date: August 12, 2021 Time: 2:00 PM Eastern Dial-in numbers: 877-876-9173 Conference ID: QUOTEMEDIA An audio rebroadcast of the call will be available later at: www.quotemedia.com About QuoteMedia QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies....

Continue reading

Lightbridge Provides Business Update and Announces Second Quarter 2021 Financial Results

Conference Call on Monday, August 9, 2021, at 4pm ET RESTON, Va., Aug. 09, 2021 (GLOBE NEWSWIRE) — Lightbridge Corporation (NASDAQ: LTBR), an advanced nuclear fuel technology company, announced financial results for the second quarter ended June 30, 2021, and provided an update on the Company’s continued progress. Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented, “We are pleased with the strong progress of our fuel development activities thus far in 2021, including the successful demonstration of our proprietary coextrusion manufacturing process. We produced rods of a length designed for small modular reactors, using nuclear-grade zirconium alloy cladding material and a displacer produced from nuclear-grade zirconium, and surrogate materials that mimic the relevant properties of uranium.” “Lightbridge...

Continue reading

Viper Energy Partners LP, a Subsidiary of Diamondback Energy, Inc., Announces Midland Basin Acquisition

MIDLAND, Texas, Aug. 09, 2021 (GLOBE NEWSWIRE) — Viper Energy Partners LP (NASDAQ:VNOM) (“Viper” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG) (“Diamondback”), today announced it has entered into a definitive purchase and sale agreement to acquire certain mineral and royalty interests from Swallowtail Royalties LLC and Swallowtail Royalties II LLC (collectively, “Swallowtail” or the “Seller”) in exchange for 15.25 million units of Viper common stock and $225 million of cash, subject to customary adjustments. The cash portion of this transaction is expected to be funded through a combination of cash on hand and borrowings under the Company’s credit facility. ACQUISITION OVERVIEW2,302 net royalty acres primarily in the Northern Midland Basin; roughly 65% of acreage is operated by Diamondback Expected...

Continue reading

FIRST OPERATIONAL MONTH OF PLAY A SUCCESS

Highest on-time performance of all airlines from Keflavik Iceland in July   Load factor was 41.7%   New pandemic restrictions negatively impacted travel trend in July July was the first operational month for PLAY and, as such, was a success.  PLAY’s main objective was to begin operation in a safe and trustworthy manner while focusing on the satisfaction of passengers. A key indicator of that success is the fact that PLAY had the highest on-time performance of all airlines operating to and from Keflavik Iceland in July, with 96.2% of all PLAY flights arriving on schedule.     PLAY received three A321 neo aircraft this summer following a very efficient and professional effort from its technical and operations teams. These aircraft will come into operation in line with the market demand while utilizing very favorable leasing terms that...

Continue reading

Immunovant Reports Financial Results for the Quarter Ended June 30, 2021

Company Ended the Quarter With Cash of Approximately $379 Million and Subsequently Received a Direct Investment of $200 Million from Roivant NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal first quarter ended June 30, 2021. Immunovant ended the quarter with approximately $379 million in cash. “We are excited to announce that in July 2021, the FDA granted Orphan Drug Designation to IMVT-1401 for treatment of Myasthenia Gravis,” said Pete Salzmann, M.D., Chief Executive Officer of Immunovant. “We have also initiated engagement with the FDA’s Division of Neurology to discuss protocol modifications for a pivotal study in Myasthenia Gravis and our...

Continue reading

Lottery.com and Coinstar Join Forces to Market Lottery Games Across the U.S.

Coinstar to join Lottery.com’s Affiliate Program AUSTIN, Texas and BELLEVUE, Wash., Aug. 09, 2021 (GLOBE NEWSWIRE) — AutoLotto, Inc. (“Lottery.com”), a leading technology company that is transforming how, where and when the lottery is played, today announced that Coinstar, LLC (“Coinstar”®), a global leader in self-service coin counting, is joining Lottery.com’s affiliate program.  Through its agreement with Lottery.com, Coinstar will market and promote Lottery.com products in California, Texas, Pennsylvania, Michigan and other U.S. jurisdictions where Lottery.com currently offers its services by utilizing its network of 4,450 interactive kiosks in these areas, including ones equipped with adPlanet™ lead generation technology. The addition of Coinstar will expand Lottery.com’s existing affiliate program, which includes leading...

Continue reading

Glucose Health, Inc. Reports Fiscal 2021 YTD Revenue Up 123% and New Amazon Sales Record

BENTONVILLE, AR, Aug. 09, 2021 (GLOBE NEWSWIRE) — Glucose Health, Inc. (OTC Pink: GLUC) (“Company”) is pleased to highlight key financial information detailed in its June 30, 2021 Quarterly Report, posted this morning at OTCMarkets.com.YTD Fiscal 2021 Revenue of $524,568 vs. $234,752 for YTD Fiscal 2020 – an increase of 123% Q2 Fiscal 2021 Revenue of $287,103 vs. $151,139 for Q2 Fiscal 2020 – an increase of 89% YTD Fiscal 2021 Gross Profit of $217,794 vs. $96,886 for YTD Fiscal 2020 – an increase of 125% Q2 Fiscal 2021 Gross Profit of $102,923 vs. $69,906 for YTD Fiscal 2020 – an increase of 47%GLUCODOWN® sales at Amazon for April 2021, the first month of Q2, reached a new monthly record of $74,944, beating the previous monthly sales record of $38,595 announced by the Company for June 2020, by 94%. Important:  Additional...

Continue reading

Syneos Health Reports Second Quarter 2021 Results

HighlightsSecond quarter revenue of $1,282.6 million, increased 6.1% sequentially and 26.6% year-over-year. Clinical Solutions net new business awards of $1,436.2 million for the second quarter, representing year-over-year growth of 21.2% and a book-to-bill ratio of 1.45x, and $4,971.5 million for the trailing twelve months, representing year-over-year growth of 8.2% and a book-to-bill ratio of 1.37x. Commercial Solutions net new business awards of $273.6 million for the second quarter, representing year-over-year growth of 55.3% and a book-to-bill ratio of 0.94x, and $1,257.4 million for the trailing twelve months, representing year-over-year growth of 4.8% and a book-to-bill ratio of 1.14x. Year-over-year ending backlog growth of 21.5% in Clinical Solutions and 17.8% in Deployment Solutions as of June 30, 2021. GAAP net income of $41.9...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.